166 related articles for article (PubMed ID: 30880685)
1. Discovery and characterization of a novel HCV inhibitor targeting the late stage of HCV life cycle.
Park SB; Boyer A; Hu Z; Le D; Liang TJ
Antivir Ther; 2019; 24(5):371-381. PubMed ID: 30880685
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of presenilin inhibitor LY411575 on maturation of hepatitis C virus core protein, production of the viral particle and expression of host proteins involved in pathogenicity.
Otoguro T; Tanaka T; Kasai H; Yamashita A; Moriishi K
Microbiol Immunol; 2016 Nov; 60(11):740-753. PubMed ID: 27797115
[TBL] [Abstract][Full Text] [Related]
3. A Novel Small Molecule Inhibits Hepatitis C Virus Propagation in Cell Culture.
Oraby AK; Gardner CL; Needle RF; Kofahi HM; Everard KR; Taylor NGA; Rutihinda SG; Barry JP; Hirasawa K; Georghiou PE; Russell RS
Microbiol Spectr; 2021 Sep; 9(1):e0043921. PubMed ID: 34319169
[TBL] [Abstract][Full Text] [Related]
4. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
5. Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles.
Hu L; Li J; Cai H; Yao W; Xiao J; Li YP; Qiu X; Xia H; Peng T
Antiviral Res; 2017 Dec; 148():5-14. PubMed ID: 29074218
[TBL] [Abstract][Full Text] [Related]
6. Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly.
Neveu G; Barouch-Bentov R; Ziv-Av A; Gerber D; Jacob Y; Einav S
PLoS Pathog; 2012; 8(8):e1002845. PubMed ID: 22916011
[TBL] [Abstract][Full Text] [Related]
7. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
Suzuki T
Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
[TBL] [Abstract][Full Text] [Related]
8. Modulation of host metabolism as a target of new antivirals.
Ikeda M; Kato N
Adv Drug Deliv Rev; 2007 Oct; 59(12):1277-89. PubMed ID: 17897752
[TBL] [Abstract][Full Text] [Related]
9. Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment.
Nio Y; Hasegawa H; Okamura H; Miyayama Y; Akahori Y; Hijikata M
Antiviral Res; 2016 Aug; 132():262-7. PubMed ID: 27392483
[TBL] [Abstract][Full Text] [Related]
10. A small-molecule inhibitor of hepatitis C virus infectivity.
Bush CO; Pokrovskii MV; Saito R; Morganelli P; Canales E; Clarke MO; Lazerwith SE; Golde J; Reid BG; Babaoglu K; Pagratis N; Zhong W; Delaney WE; Paulson MS; Beran RK
Antimicrob Agents Chemother; 2014; 58(1):386-96. PubMed ID: 24165192
[TBL] [Abstract][Full Text] [Related]
11. Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents.
Shahidi M; Tay ESE; Read SA; Ramezani-Moghadam M; Chayama K; George J; Douglas MW
J Gen Virol; 2014 Nov; 95(Pt 11):2468-2479. PubMed ID: 25053565
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C Viral Replication Complex.
Li HC; Yang CH; Lo SY
Viruses; 2021 Mar; 13(3):. PubMed ID: 33809897
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay.
Hu Z; Hu X; He S; Yim HJ; Xiao J; Swaroop M; Tanega C; Zhang YQ; Yi G; Kao CC; Marugan J; Ferrer M; Zheng W; Southall N; Liang TJ
Antiviral Res; 2015 Dec; 124():20-9. PubMed ID: 26515788
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
15. Arrest all accessories--inhibition of hepatitis C virus by compounds that target host factors.
von Hahn T; Ciesek S; Manns MP
Discov Med; 2011 Sep; 12(64):237-44. PubMed ID: 21955851
[TBL] [Abstract][Full Text] [Related]
16. [Anti-hepatitis C Virus Strategy Targeting the Entry Steps].
Fukasawa M
Yakugaku Zasshi; 2019; 139(1):89-95. PubMed ID: 30606936
[TBL] [Abstract][Full Text] [Related]
17. Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry.
Chung CY; Liu CH; Burnouf T; Wang GH; Chang SP; Jassey A; Tai CJ; Tai CJ; Huang CJ; Richardson CD; Yen MH; Lin CC; Lin LT
Antiviral Res; 2016 Jun; 130():58-68. PubMed ID: 27012176
[TBL] [Abstract][Full Text] [Related]
18. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P; Sarrazin C
Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
[TBL] [Abstract][Full Text] [Related]
19. The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.
Gallay PA; Bobardt MD; Chatterji U; Trepanier DJ; Ure D; Ordonez C; Foster R
PLoS One; 2015; 10(8):e0134707. PubMed ID: 26263487
[TBL] [Abstract][Full Text] [Related]
20. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
